NCT06495190 · RECRUITING

Cognition, Flavonoids, Exercise, Gut Microbiome

This NIH-funded trial is testing whether eating blueberries daily for 12 weeks, combined with regular brisk walking, slows mild age-related cognitive decline in older adults. Researchers will also look at whether the gut microbiome plays a role in any benefit. It is a Phase N/A trial, meaning it is a behavioral and dietary intervention study, not a drug trial, and no FDA approval process applies.

You may qualify if

  • Score on the Montreal Cognitive Assessment (MoCA test) of 24.1-25.2 that indicates mild cognitive decline. The MoCA test score ranges from 0 to 30, with higher scores from 26 to 30 considered normal.
  • Healthy, non-smoking male or female participants 65 to 85 years of age.
  • Capable of engaging in a supervised 12-week exercise training program (brisk walking or stretching).
  • Physically inactive (defined as less than 150 min/week moderate or less than 75 minutes vigorous aerobic and/or resistance exercise during the past 4 weeks).
  • Willingness to be randomized to one of four groups.
  • Willingness to provide blood, urine, and fecal samples (3 each),
  • Willingness to avoid blueberry intake during the 12-weeks study (other than what is provided through the study).
  • Willingness to maintain current diet and physical activity patterns during the study (other than what is prescribed as a part of the study), and make no formal attempts to lose or gain body weight.
  • Willingness to be a participant in this study only and not enter any other studies.

You're excluded if

  • Allergy to blueberries.
  • Diagnosis of Type I or Type 2 diabetes.
  • Chronic cardiovascular, metabolic, or renal condition that is uncontrolled (controlled defined as stable for 6 months or more).
  • History of signs or symptoms during rest or physical activity such as chest discomfort, unreasonable breathlessness, dizziness, fainting, or blackouts.
  • Use of any prescription or over-the-counter drug intended to support cognition or with known cognitive side effects.
  • Any other concurrent condition or use of medications or supplements which, in the opinion of the study clinician would preclude participation in this study.
  • Diagnosis of dementia.

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2025-03-12

View full record on ClinicalTrials.gov

All APOE4 clinical trials